Frazier Lifesciences Acquisition Co. (NASDAQ:FLAC) Short Interest Update

Frazier Lifesciences Acquisition Co. (NASDAQ:FLACGet Rating) saw a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 2,200 shares, a decrease of 89.5% from the April 15th total of 20,900 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 35,500 shares, the days-to-cover ratio is presently 0.1 days.

A number of hedge funds have recently made changes to their positions in the stock. EcoR1 Capital LLC boosted its holdings in Frazier Lifesciences Acquisition by 193.1% in the third quarter. EcoR1 Capital LLC now owns 587,615 shares of the company’s stock valued at $5,770,000 after acquiring an additional 387,120 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Frazier Lifesciences Acquisition by 406.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 508,840 shares of the company’s stock valued at $4,961,000 after acquiring an additional 408,365 shares during the last quarter. Ensign Peak Advisors Inc bought a new stake in Frazier Lifesciences Acquisition in the fourth quarter valued at approximately $4,388,000. Picton Mahoney Asset Management boosted its holdings in Frazier Lifesciences Acquisition by 150.0% in the first quarter. Picton Mahoney Asset Management now owns 249,996 shares of the company’s stock valued at $2,460,000 after acquiring an additional 150,000 shares during the last quarter. Finally, Saba Capital Management L.P. bought a new stake in Frazier Lifesciences Acquisition in the fourth quarter valued at approximately $2,392,000. Institutional investors and hedge funds own 45.63% of the company’s stock.

Frazier Lifesciences Acquisition stock opened at $9.85 on Thursday. The business has a 50 day moving average of $9.84 and a 200-day moving average of $9.80. Frazier Lifesciences Acquisition has a 1 year low of $9.65 and a 1 year high of $10.02.

About Frazier Lifesciences Acquisition (Get Rating)

Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.

Further Reading

Receive News & Ratings for Frazier Lifesciences Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frazier Lifesciences Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.